KRAS

[Oncogene] Researchers identified a key regulator of macropinocytosis for the survival of tumor cells in a low amino acid environment in pancreatic ductal adenocarcinoma.

[Scientific Reports] Researchers evaluated combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 in TP53 wild-type and mitogen-activated protein kinase (MAPK) altered colon and thyroid cancer models.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers demonstrated that the multispecificity BET/EP300 inhibitor XP-524 has pronounced single-agent efficacy in vitro, in vivo, and ex vivo human PDAC slice cultures, functioning in part by attenuating oncogenic KRAS signaling.

[Amgen, Inc.] Amgen announced that LUMAKRAS® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer that has progressed after systemic anticancer therapy.

[Carcinogenesis] Researchers demonstrated that perfluorooctanoic acid induced oxidative stress and focal ductal hyperplasia in the mouse pancreas.

[ACS Medicinal Chemistry Letters] The first hydrophobic tagging-based PDEδ degraders were designed. Compound 17c efficiently bound to PDEδ and induced degradation of PDEδ in SW480 colon cancer cells.